Evidenzbasierte Therapie von Hyperphosphatämie und Vitamin-D-Mangel

Gunnar Henrik Heine

doi:10.1055/a-2415-9576

Nephrologie aktuell, Table of Contents

Nephrologie aktuell 2024; 28(10): 464-471
DOI: 10.1055/a-2415-9576

Schwerpunkt

Nephrologie

Evidenzbasierte Therapie von Hyperphosphatämie und Vitamin-D-Mangel

Wieviel Intervention ist in Zeiten der SGLT-2-Hemmer erforderlich?

Gunnar Henrik Heine

¹Agaplesion Markus Krankenhaus, Frankfurt am Main

› Author Affiliations

Abstract

ZUSAMMENFASSUNG

Patienten mit einer chronischen Nierenkrankheit (CKD: „chronic kidney disease“) weisen eine hohe kardiovaskuläre Morbidität und Mortalität auf. Auf traditionelle Risikofaktoren der Atherosklerose zielende Strategien, die in der Allgemeinbevölkerung erfolgreich sind, erbringen jedoch bei schwerer CKD keinen eindeutigen Benefit. Daher haben Präventionsstrategien bei CKD lange auf nichttraditionelle Risikofaktoren fokussiert – insbesondere auf Komponenten der CKD-assoziierten Mineral- und Knochenstörungen (CKD-MBD: „chronic kidney disease – mineral and bone disorder“). Allerdings ist die Evidenz für eine kardiovaskuläre Risikoreduktion durch die Therapie der CKD-MBD begrenzt. Jenseits der CKD-MBD sind nun mit SGLT-2-Inhibitor (SGLT-2: „sodium-glucose linked transporter 2“), GLP-1-Analoga (GLP-1: „glucagon-like peptide-1“) und nichtsteroidalem Mineralo-Kortikoid-Rezeptor-Antagonist Pharmaka verfügbar, die in Phase-III-Studien eine klare kardiovaskuläre Risikoreduktion erlaubt haben und zudem bei nichtdialysepflichtiger CKD nephroprotektiv sind. Daher sollten nun Therapiestrategien der CKD-MBD kritisch reevaluiert werden.

Full Text

References

Literatur
1 Lindner A, Charra B, Sherrard DJ. et al Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701
2 Go AS, Chertow GM, Fan D. et al Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
3 Van Der Velde M, Matsushita K, Coresh J. et al Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79: 1341-52
4 Wanner C, Krane V, März W. et al Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248
5 Fellström BC, Jardine AG, Schmieder RE. et al Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
6 Heine GH, Nangaku M, Fliser D. Calcium and phosphate impact cardiovascular risk. Eur Heart J 2013; 34: 1112-1121
7 Heine GH. Mineral metabolism in heart disease. Curr Opin Nephrol Hypertens 2015; 24: 310-316
8 Ketteler M, Bover J, Mazzaferro S. Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022 s. Nephrol Dial Transplant 2023; 38: 1397-1404
9 Brandenburg V, Ketteler M. Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future. Nutrients 2022; 14: 3009
10 Jørgensen HS, de Loor H, Billen J. et al Vitamin D metabolites before and after kidney transplantation in patients who are anephric. Am J Kidney Dis 2024; 84: 427-436.e1
11 Manson JE, Cook NR, Lee I-M. et al Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med 2019; 380: 33-44
12 Limonte CP, Zelnick LR, Hoofnagle AN. et al Effects of vitamin D3 supplementation on cardiovascular and cancer outcomes by eGFR in VITAL. Kidney360 2022; 3: 2095-2105
13 De Boer IH, Zelnick LR, Ruzinski J. et al Effect of vitamin D and Omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: A randomized clinical trial. JAMA 2019; 322: 1899-1909
14 Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration. Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. Lancet Diabetes Endocrinol 2024; 12: e2-e11
15 Thadhani R, Appelbaum E, Pritchett Y. et al Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 2012; 307: 674-684
16 Wang AYM, Fang F, Chan J. et al Effect of paricalcitol on left ventricular mass and function in CKD – The OPERA trial. J Am Soc Nephrol 2014; 25: 175-186
17 J-DAVID Investigators, Shoji, T, Inaba M et al. Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism receiving maintenance hemodialysis: the J-DAVID randomized clinical trial. JAMA 2018; 320: 2325-2334
18 Ogata H, Fukagawa M, Hirakata H. et al Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the LANDMARK randomized clinical trial. JAMA 2021; 325: 1946-1954
19 Lioufas NM, Pascoe EM, Hawley CM. et al Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol 2022; 33: 59-76
20 Edmonston DL, Isakova T, Dember LM. et al Design and rationale of HiLo: a pragmatic, randomized trial of phosphate management for patients receiving maintenance hemodialysis. Am J Kidney Dis 2021; 77: 920-930.e1
21 EVOLVE Trial Investigators, Chertow GM, Block GA et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494
22 Middleton JP, Wolf M. Second chances to improve ESRD outcomes with a second-generation calcimimetic. JAMA 2017; 317: 139-141
23 Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs — insights from the rosiglitazone experience. N Engl J Med 2013; 369: 1285-1287
24 Wanner C, Inzucchi SE, Lachin JM. et al Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334
25 Mann JFE, Ørsted DD, Brown-Frandsen K. et al Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839-848
26 The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388: 117-127
27 Heerspink HJL, Stefánsson BV, Correa-Rotter R. et al Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436-1446
28 Perkovic V, Tuttle KR, Rossing P. et al Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391: 109-121
29 Pitt B, Filippatos G, Agarwal R. et al Cardiovascular events with finerenone in kidney disease and type 2 diabetes. NEngl J Med 2021; 385: 2252-2263
30 Bakris GL, Agarwal R, Anker SD. et al Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383: 2219-2229
31 Lewis EJ, Hunsicker LG, Bain RP. et al The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
32 Parving HH, Lehnert H, Brochner-Mortensen J. et al The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
33 Brenner BM, Cooper ME, de Zeeuw D. et al Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
34 Neuen BL, Heerspink HJL, Vart P. et al Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 2024; 149: 450-462
35 Rau M, Thiele K, Hartmann NUK. et al Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – data from a randomized, placebo-controlled study. Bone Rep 2022; 16: 101175
36 Neuen BL, Tuttle KR, Vaduganathan M. Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease. Circulation 2024; 149: 1238-1240
37 Baigent C, Landray MJ, Reith C. et al The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192
38 März W, Genser B, Drechsler C. et al Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 2011; 6: 1316-1325